Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma (Q67801961)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1991

Language	Label	Description	Also known as
English	Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma	scientific article published on 01 January 1991

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

G G Hermann

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

P F Geertsen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

H von der Maase

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

J Zeuthen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

111-114

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1760814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

https://scigraph.springernature.com/pub.10.1007/bf01741344

0 references

VLA proteins in the integrin family: structures, functions, and their role on leukocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A classification of human urothelial cells propagated in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/1760814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67801961&oldid=1754342883"